Peptide LibraryThymogen (Oglufanide) dosage in published studies and labels
These are the doses used for Thymogen (Oglufanide) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Thymogen (Glu-Trp) has human doses from trials, but no dose with proven benefit. As the drug candidate IM862 (oglufanide), it was given as nose drops in US and UK cancer trials: 5 mg every other day in AIDS-related Kaposi's sarcoma, which a 202-patient phase 3 trial found no better than placebo, and 20 mg three times a day in kidney cancer, which produced no responses. A Russian placebo-controlled study gave thymogen as nose drops for 7 days before surgery. It is not FDA-approved.
| Human dosing established | Yes |
|---|---|
| Route | Intranasal (all trials with a stated route) |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| IM862 (oglufanide) in AIDS-related Kaposi's sarcoma, phase 3 (2005)Clinical trial · Phase 3 randomised double-blind placebo-controlled trial | HIV-positive adults with Kaposi's sarcoma (n=202; 104 IM862, 98 placebo) | 5 mg | Intranasal | Every other day | 24 weeks planned (median 19.5 weeks on IM862) | Response rate no better than placebo (23% vs 21%); shorter time to progression on IM862 | Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy. J Clin Oncol. 2005. |
| IM862 (oglufanide) in AIDS-related Kaposi's sarcoma, randomised schedule study (2000)Clinical trial · Randomised comparison of two dosing schedules, no placebo | Adults with AIDS-related Kaposi's sarcoma (n=44) | 5 mg | Intranasal drops | 5 days on and 5 days off (n=18), or every other day (n=26) | Repeated cycles until progression or unacceptable toxicity | Major responses in 36%; mild, short-lived headache, fatigue, tingling and nausea | Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000. |
| IM862 (oglufanide) in metastatic renal cell carcinoma, phase 2 (2004)Clinical trial · Phase 2 single-arm trial | Adults with metastatic renal cell carcinoma (n=25) | 20 mg | Intranasal | Three times a day | 8-week cycles | No objective responses; 8 patients had stable disease; no grade 2 or 3 drug-related toxicity | Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer. 2004. |
| Thymogen before abdominal tumour surgery in older patients (2011)Clinical trial · Randomised double-blind placebo-controlled study, Russian-language publication | Older adults having surgery for abdominal or retroperitoneal solid tumours (number not stated in the indexed abstract) | 100 mg once a day, as stated in the English abstract (not checked against the Russian full text) | Intranasal instillation | Once a day | 7 days before surgery | Fewer post-operative complications and a shorter post-operative period reported | [Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity]. Adv Gerontol. 2011. |
| NCT00003773 — phase 1, IM862 (oglufanide disodium) in recurrent ovarian cancerClinical trial · Phase 1 dose-escalation trial | Patients with recurrent ovarian cancer (n=43) | Escalating doses to find the maximum tolerated dose (not stated in the record) | Intranasal | Daily | 6 months | Completed; no results posted | NCT00003773 — IM-862 in Treating Patients With Recurrent Ovarian Cancer |
Where sources disagree
- The trialled doses differ by more than tenfold (5 mg every other day, 20 mg three times a day, and 100 mg a day in one Russian abstract), so no single figure summarises them. The 100 mg figure is as printed in the English abstract and could not be checked against the Russian text.
- The only phase 3 trial found IM862 no better than placebo for Kaposi's sarcoma, and the kidney cancer trial found no responses. A trial dose is not evidence that the dose works.
- The 2004 kidney cancer abstract describes IM862 as L-Glu-L-Trp, the thymogen dipeptide, and the trial registry names it oglufanide disodium. The 2005 phase 3 abstract instead calls it L-glutamine L-tryptophan.
- Russian clinical papers on thymogen in infection, tuberculosis and diabetes exist, but their indexed abstracts do not give a usable dose. Thymogen is not FDA-approved and has no DailyMed listing.